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ABSTRACT
ENHANCEMENT OF LATERAL FLOW ASSAY FOR THE DETECTION OF
WHOLE VIRAL PARTICLE AND CHLAMYDIAL ELEMENTARY BODIES
FEBRUARY 2014
JEFFREY M. GRIMES, B.S., UNIVERSITY OF CENTRAL FLORIDA
M.S., UNIVERSITY OF MASSACHUSETTS AT AMHERST
Directed by: Professor Sam Nugen
Chlamydia trachomatis accounts for 3.6% of blindness worldwide, and is the
leading cause of bacterial-induced blindness in the world. With the subtle initial
presentation of the disease and the difficulty in clearing the infection without the aid of
antibiotics, C. trachomatis can spread rapidly following introduction into a population.
This problem is further compounded in resource limited areas due to the lack of trained
personnel (i.e. Medical Doctors, Nurses), equipment, and finances to test and treat large
portions of the population. A testing method that is both cheap and easy to interpret is
necessary. Lateral flow assays (LFA) have been used for years to evaluate pregnancy
status in the developed world, and their low cost, ease of use and disposable nature make
them a worthwhile candidate, but the current use of visual reporters (i.e. gold or latex
nanoparticles) does not allow for adequate sensitivity for true clinical use. Fluorescent
reporters, particularly fluorescent nanoparticles, would lower the limit of detection
(LOD) and allow for the detection of acute and subclinical infections, which would allow
for an effective and objective screening method for trachoma and many other diseases.
An effective, rapid, and disposable test would allow for mass screening to be
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implemented which, in turn, would allow for rapid and targeted treatment. The results in
this study show that the use of fluorescent-based reporters greatly improve the LOD of
the LFA, with both FITC and RuSNP reporters showing a reduction in the LOD by 1 and
2.5 logs respectively when compared to traditional colorimetric reporters. This substantial
improvement in the LOD of the LFA allows for the tests to be used to detect relevant
levels of viral pathogens. A similar improvement in the LOD was seen when using FITClabeled antibodies which improved the sensitivity of LFAs with regards to the detection
of C. trachomatis. The use of fluorescent-based reporters in LFAs greatly improves the
LOD for both viruses and bacteria, allowing for their detection at clinically relevant
levels.
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CHAPTER 1
INTRODUCTION
Diagnostics play a critical role in health care worldwide, allowing for the
verification of the integrity of the food/water supply and allowing for effective
monitoring and timely treatment of diseases. The benefits of a wide-spread and
comprehensive diagnostic monitoring program for endemic disease can be best
exemplified in the decrease and resurgence of African sleeping sickness, which reached
historic lows (< 2000 reported new cases) in the 1960’s predominantly due to widespread screening, but steadily rose as funding for the monitoring and control measures
fell off [1-3]. While the necessity for diagnostics is ubiquitous, the political, social, and
health care infrastructures that are paramount to the introduction of effective health care
vary greatly between countries [4–6]. Further complicating the issue, the current gold
standard diagnostic tools (i.e. Polymerase Chain Reaction (PCR), culture) are too costly
for a comprehensive screening of an entire population [6].

While the burden of disease in the developed world is predominantly lifestyle
related, the developing world suffers greatly from communicable diseases and,
increasingly, lifestyle diseases as the average life span continues to increase [5, 7]. The
current cost and limited availability of trained personnel capable of employing modern
diagnostic tools leads to a large population which is left undiagnosed and untreated for
serious illness [7-9]. The development, and therefore the availability, of cheap
diagnostics has lagged behind, mostly due to funding being predominantly focused
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towards the development of new antibiotics and vaccines. Recent developments such as
the rise of antibiotic resistance, the threat of pandemics due to globalization, and the
spread of disease with no current cure ( i.e. Human Immunodeficiency virus (HIV)) have
led to increases in funding for Point of care (POC) diagnostics. Increased funding for
low-cost POC diagnostics, coupled with the advancement of lab-on-chip and smart phone
technology, is allowing for a greater degree of sensitivity and accuracy, generating results
that are nearing the sensitivity of PCR [2–5]. The currently deployed POC diagnostic
tests have a high rate of error (19%-96% accuracy) however, as they depend heavily on
the end user’s ability to follow and execute instructions [7-13]. As the optimal test would
be simple for a lay person to use, greater sensitivity and fidelity is needed to compensate
for end-user error, while keeping the test simple and inexpensive.

1.1 Chlamydia trachomatis
Chlamydia trachomatis is an obligate intracellular Gram-negative bacterium,
belonging to the family Chlamydiaceae and the genus Chlamydia. There are nine species
in the genus Chlamydia, with C. trachomatis and C. pneumoniae being prominent human
pathogens [14]. C. trachomatis is the causative agent of trachoma, a disease that is
responsible for 3% (~39 million cases worldwide) of reported cases of blindness,
predominantly in tropical developing countries with limited resources. C. trachomatis is
also a prominent causative agent of several sexually transmitted diseases (STDs). With
more than 92 million new cases occurring worldwide each year, C. trachomatis is the
largest single cause of bacterial-induced STDs and blindness globally [15-19]. Due to the
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ability of C. trachomatis to invade numerous tissues, this one bacterium can elicit a wide
range of STDs, including ophthalmia neonatorum and pneumonitis in infants, pelvic
inflammatory disease (PID), proctitis, urethritis, cervicitis, inguinal lymphadenitis and
reactive arthritis in adolescents and adults. C. trachomatis has also been correlated to
squamous-cell carcinoma of the uterine cervix and is a complicating and enhancing factor
in HIV-1 infection and transmission [20-24]. Issues stemming from Chlamydia are
compounded by the fact that large percentages of the infected population are
asymptomatic for urogenital infections, meaning that ~ 80% of women and ~ 50% of men
are left untreated. This wide-spread sub-clinical population has the potential to cause
numerous new cases of C. trachomatis infections and acts as a large reservoir for the
disease, which perpetuates several STDs [25-27]. Another complicating factor is that
protective immunity appears to be transient. This is due to C. trachomatis actively downregulating MHC class I and class II antigen presenting pathways, which is a contributing
factor to the large number of asymptomatic infections [28].

The development of an inexpensive, rapid, accurate, and simple test is needed for
wide-spread screening of C. trachomatis to be a viable option. The currently deployed
methods for screening for C. trachomatis are not viable for a large population, making
the development of a cost effective screening method invaluable in decreasing the
morbidity from C. trachomatis infections [29, 30]. Furthermore, while many C.
trachomatis infections are thought to be effectively treated by antibiotics, follow-up
studies have revealed that numerous patients develop re-infection, treatment failure or C.
trachomatis persistence [31-37].
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1.2 Trachoma
1.2.1 Trachoma Pathology and Clinical Features
The causative agent of endemic trachoma are four serovars (A, B, Ba, and C) of
C. trachomatis, and while other serovars can causes conjunctiva these are isolated
incidents, and do not lead to blinding. The first acquisition of trachoma likely occurs at a
young age (1-10 years old), although the age of initial infection varies depending on the
prevailing level of infection of the region, with hyper-endemic levels leading to
infections in infants [37, 38].

Following initial infection, C. trachomatis appears to spread only to surrounding
epithelium and does not penetrate in to deeper tissues. The clinical signs of active
trachoma are a result of the host immune system reacting to the infection, with typical
signs including marked inflammatory cell infiltrate and the release of pro-inflammatory
cytokines in the conjunctiva [39-41]. The clinical symptoms are papillary with or without
follicular inflammation of the tarsal conjunctiva. As the infection is resolved the visible
inflammation gradually subsides. There is a large correlation between age and active
trachoma infections, with the prevalence and duration of the infection decreasing with
age, implying that a maturation of the immune response is occurring [42, 43]. Yet, the
development of an effective vaccine has proven difficult, as the immunity acquired
appears to be transient and strain specific, leading to repeated infections in endemic
environments [44, 45]. The reoccurring infections lead to chronic inflammation, causing
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scar tissue to build within in the conjunctiva over time [46, 47]. Following sufficient
accumulation, the scar tissue will contract, causing the eyelids to roll inwards towards the
eye (entopion) and allowing the eyelashes to scratch the cornea (trichiasis). The most
debilitating disease from trachoma is blindness due to corneal opacification (CO), which
is severe corneal damage due in part to trichiasis. Trichasis alone is not able to cause CO,
however, and a number of other factors contribute, such as chronic inflammation of the
conjunctiva and additional bacterial infections [48, 49].

1.2.2 Epidemiology
While trachoma affects large portions of the globe (see figure 1), with blinding
trachoma endemic in 56 countries, Sub-Saharan Africa has the highest prevalence of
active trachoma and trichiasis [49-51]. In 2012, the World Health Organization (WHO)
reported ~22 million cases of active trachoma and ~7.2 million cases with trichiasis. Prior
to that, WHO’s comprehensive burden of disease study, released in 2004, suggested that
the prevalence of disease was ~40 million people with active trachoma and ~8.2 million
with trichiasis [53]. These current estimates represent a substantial decrease, as the
previous study estimated the current burden of active trachoma at ~84 million [54]. The
substantial decrease in estimated cases has been linked in part to over-estimations of the
burden of active trachoma in India and China. In the past, trachoma had a far wider
distribution, affecting both Europe and North America. As sanitation and living
conditions improved, manifestations of trachoma declined, and currently trachoma is not
a health risk in Europe or North America, despite a large population infected with C.
trachomatis [55].
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While clinical manifestations of trachoma vary with age, young children act as the
main reservoirs for active trachoma infections, and as they age the frequency and
duration of the infection decreases [56, 57]. The conjunctival scarring that occurs
accumulates with age and repeated infections, and does not typically become evident
until the second or third decade of life [58,59]. The more severe repercussions of
trachoma, such as Entropion, trichiasis, and CO, tend to develop later in life, but in
hyper-endemic regions blinding can occur in children [60]. Women have been found to
suffer trichiasis and CO at a higher rate than men, likely due to women having closer
contact and greater interaction with children, the main reservoir of disease [59,61].

Risk factors for trachoma are typically related to increasing the transmission of C.
trachomatis from infected to non-infected individuals [62]. Copious secretions found
around the eyes have consistently been associated with active trachoma, and close contact
with these secretions promotes transmission and attracts flies, which act as vectors for
transmission. Another risk factor is the scarcity of water and its related cleanliness, as
face washing reduces the transmission of C. trachomatis. An additional compounding
factor is the lack of latrines, as fecal contamination provides breeding material for the
flies [63]. Crowded living conditions and limited resources are additional factors that
promote transmission. In resource-limited areas, the slow development of changes needed
to reduce the burden of trachoma, coupled with current demographic trendsand the lack
of effective control programs, predicts an increase in the total number of people blinded
by trachoma [64]
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Figure 1. Global Distribution of Trachoma. Countries colored deep orange are those
with endemic trachoma while those colored light blue are those being monitored for
trachoma. The uncolored countries have no reported incidence of trachoma. These data
are based on WHO’s Global Study of Disease 2008 [54]. The map of the earth is open
source from http://misterjogja.com/wp-content/uploads/2013/04/blank-world-map-qh51jnua.jpg
and it was hand-colored by the author.

1.2.3 Burden of Trachoma
The global burden due to trachoma is not heavily influenced by mortality, but
rather morbidity, mainly due to visual impairment and trichiasis. The visual impairment
is divided into two categories: Blindness and Low Vision. Blindness, as defined by
WHO, is visual acuity of less than 3/60 (20/400, ICD-10 visual impairment categories 3,
4, and 5). Low Vision, as defined by WHO, is visual acuity of less than 6/18 (20/60, ICD10 visual impairment categories 1 and 2) [65]. The visual impairment or blindness has a
profound effect beyond the individual, as the person’s ability to function and provide for
his/her family is severely reduced, often creating a greater burden on the family and
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community. This in turn helps to perpetuate the poverty, shown to be a contributing
factor in contracting trachoma. Trichiasis, while not immediately inducing blindness, has
a major impact on quality of life and can affect functionality in everyday life, typically by
causing pain and photophobia. A study of women from Tanzania showed that sufferers of
trichiasis without visual impairment sustained comparable disability to those individuals
with visual impairment induced from sources other than trachoma [66].

The difficulty in estimating the burden of disease induced by trachoma is that it
does not cause mortality rapidly or directly, but rather induces morbidity, and so new
measures were developed to evaluate the burden caused by trachoma. These measures
were developed in the Global Burden of Disease study (GBD) [67]. The GBD study
developed a new measure of the burden of disease: Disability-Adjusted Life Years
(DALYs). This measures the gap in healthy life lost between an ‘ideal’ healthy
population and the reality caused by a specific disease in terms of premature mortality
and disability in a population. DALYs are calculated based on two major components:
premature mortality, or years of life lost (YLL), and the years of healthy life lost due to a
disability caused by a disease, years of life lived with a disability (YLD). YLD is a
weighted measurement based on the number of people dying or disabled from a disease
in a given population which allows for the severity of the disability to be taken into
account - the more severe the disability, the greater the number of YLDs that are lost
[67].
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The GBD study estimated the burden of trachoma to be about 1.3 million DALYs
annually, due mostly to YLD. This estimate used WHO figures for the number of people
affected by trachoma at that time. Another estimate was made by Frick and colleagues in
2000, but in their calculation they only used YLD, as they considered YLL estimates to
be unreliable [68]. They then re-estimated the number of people with blindness from
trachoma worldwide based on the reassessment of survey data collected since 1980.
Following that, based upon previously published data, they estimated that for each person
blinded by trachoma there were an additional 1.4 affected with low vision. These changes
lead to an estimation of the annual DALYs of 3.6 million, with sub-Saharan Africa
constituting the bulk of those affected globally at 72% [68].

Although the estimates of the burden of trachoma are a useful tool for measuring
the affect of trachoma, they are skewed due to several factors. The most significant issue
is that the calculations rely on data gathered on the prevalence of endemic trachoma, and
while the most recent estimates have become more accurate, an accurate accounting of
the global prevalence of trachoma is still difficult to obtain. Secondly, trachoma’s affect
on DALYs is predominantly measured in YLD, as there is a lack of comprehensive data
relating to the degree in which trachoma-related blindness affects premature mortality.
One study has investigated the correlation between visual impairment and increases in
mortality in rural communities located in sub-Saharan Africa. They found that blind
people had increased rates in mortality compared to sighted controls [69]. Additional
studies are needed to investigate this question for trachoma. Finally, there is some debate
over the inclusion of trichiasis as a disabling disease sequel, independent of visual
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impairment. Frick and colleges reported that trichiasis, independent of visual impairment,
increased the burden of disease caused by trachoma by as much as 50% [70].

1.2.4 Current Methods of Treatment, Control, and its Cost-Effectiveness
The current and most widely deployed method for the treatment and control of
trachoma is called SAFE: surgery for trichiasis, antibiotics for infection, facial
cleanliness, and environmental improvements to reduce transmission. The SAFE strategy
was developed and promoted by WHO and GET2020. GET2020 was established
following the 1998 World Health Assembly, which resolved to eliminate blinding
trachoma by the year 2020, and is a collaboration between the WHO, national trachoma
control organizations, industry, non-governmental organizations, and academic
institutions [71, 72].

The current body of data supports the conclusion that the SAFE strategy is
clinically effective [73]. Trichiasis surgery has been shown to effectively prevent
additional damage to the eye and prevents the onset of blindness while increasing quality
of life. However, there are several problems with both the availability of the surgery and
a patient’s willingness to undergo surgery. Even when the surgery cost is covered,
patients are at times reluctant to undergo corrective surgery due to several factors: burden
of household tasks, indirect cost of surgery, lack of companion, and fear of surgery.
Additionally, as the traveling distance increased to greater than one hour, the likelihood
that suffers of trichiasis would seek corrective surgery decreased [74]. While corrective

10

surgery is effective in the short term, one study showed that surgery alone is not effective
for combating blinding from trachoma in the long term, due to a relatively high rate of
reoccurrence of trichiasis in countries with endemic trachoma [75,76].

Antibiotic treatment reduces the risk of active trachoma and ocular chlamydial
infection in people infected with C. trachomatis, and the antibiotics regiment currently
recommended by the WHO is oral azithromycin, single dose, or topical tetracycline,
twice daily for 6 wk. In clinical trials, both of these antibiotics have been shown to be
effective at reducing the prevalence of both active trachoma and C. trachomatis infection
[77, 78]. However the clinical signs of active trachoma are subtle, and at times it is
difficult to identify a C. trachomatis infection. Compounding this issue is C. trachomatis’
ability to rapidly reemerge in populations where some infected cases are left untreated.
Systematic and opportunistic screening has been purposed as a possible method to
identify and more effectively treat chlamydial infections, but currently deployed
diagnostic methods would make such an endeavor cost prohibitive [79]. Therefore, the
current recommendation is for mass drug administration (MDA) of entire communities in
endemic regions, which are conducted annually for several years, until the prevalence of
follicular trachoma (TF) in children ages 1–9 years drops below 5% [80]. Studies show
that when yearly treatment is halted TF resurgence is observed. This was seen in two
regions of Mali, where following the cessation of a 3 year MDA program rates of TF
prevalence in children ages 1-10 yearsincreased from ~2% to ~8% [81]. Additionally,
since MDA calls for treatment until the prevalence of TF drops below 5%, large portions
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of the population are being treated with antibiotics without need, which has led to
increases in antibiotic resistant bacteria [82].

The last two components of the SAFE strategy, face washing and environmental
interventions, have mixed but limited published data supporting or refuting their
effectiveness [83]. One study showed that when health education was given, the
incidence of active trachoma was lower in the village given health education than in the
control village at six months [84]. However, a study preformed in 2010 on the effect of
health education and a clean water supply on the rate of trachoma found no statistically
significant difference between the control villages and the intervention villages [85].
Similarly, contradictory reports on the effectiveness of fly control through the use of
insecticides have been reported on. One study showed a reduction of the prevalence of
active trachoma by 55.8% while another report showed no statistically significant change
in rates of trachoma between test and control populations, 43% versus 44%, following
one year of insecticide use [85, 86]. While conclusive data is difficult to attain, historical
and observational studies strongly support the view that general improvements in hygiene
and the control of disease vectors can have a profound long-term effect on this disease
[55].

Several estimates have been made for the cost-effectiveness of the SAFE strategy.
For trichiasis surgery, the cost, varying by region, is estimated to be about 19
International Dollars (I$) per case in Africa, with a comparable cost in other resource
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limited regions. Surgery was found to be very cost-effective, with estimates ranging from
I$13 to I$78 per DALY, depending on the region [87, 88]. In contrast, the costeffectiveness of antibiotic treatment is more debatable, with estimates ranging from
I$9,000 to I$65,000 per DALY prevented. MDA does become more cost effective if the
antibiotics are either donated or sold at a reduced cost, however [87]. Several
investigators have produced estimates of the cost-effectiveness of trachoma control
programs or individual components of the SAFE strategy. A comprehensive analysis of
the entire SAFE strategy has yet to be performed.

1.3 Current Methods of Diagnostics
1.3.1 Polymerase Chain Reaction
Since PCR’s development in 1983 by Karry Mullis, it has become an
indispensable tool in the diagnosis of a wide array of disease, along with numerous other
uses [88]. PCR functions based upon the use of a thermally stable DNA polymerase,
allowing for repeated annealing and melting of the primer and template following each
round of amplification. This allows for PCR to amplify the amount of target DNA present
by several million-fold following 25 cycles. This in turn allows for a very high degree of
sensitivity, and theoretically allows for the detection of a single copy of the target DNA
[89].

For the detection of C. trachomatis, several types of PCR assays are widely
employed: ligase chain reaction and strand displacement amplification assays, both of
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which target nucleotide sequences on the cryptic plasmid, and transcription-mediated
amplification reaction, which targets ribosomal RNA. Both of these targets have multiple
copies, allowing for greater sensitivity. As there are multiple copies of the target sites,
PCR is theoretically capable of detecting less than one elementary body (EB), and has
been shown to do so in purified suspensions of Chlamydia [90]. Evaluations of these
amplification methods have demonstrated that PCR has a higher degree of sensitivity
than culture, microscopy, or current immunoassays [91, 92].

While the theoretical LOD is one copy, the actual sensitivity with clinical
specimens is lower, mostly due to sampling variability and the inhibition of the
amplification reaction from various factors in the specimens [93]. While PCR assays are
highly accurate and have a great degree of sensitivity, they all are limited in their
application as a POC diagnostic for several reasons. First, the process of PCR is easily
contaminated, and stringent handling procedures are needed in order to prevent
contamination. Secondly, while not as time intensive as culture based diagnostic
methods, the amount of time needed to properly prepare samples, perform the assay, and
interpret the results is still substantial [94]. Finally, the cost of the required equipment
and highly trained personnel to perform the PCR excludes it as a viable diagnostic test for
wide-spread use in developing countries and limited resource settings [93-95].
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1.3.2 Culture Based Diagnostics
While there have been great advances in molecular diagnostics, predominantly
due to real time PCR, the growth of Chlamydia (or any pathogen of interest) in culture is
still considered, by some, to be the gold standard for diagnostics [96, 97]. The ability to
grow Chlamydia in a cell line allows for very high degree of specificity, potentially able
to detect a single viable EB. It has further benefit over molecular diagnostic techniques in
that it will only detect infectious Chlamydia, as PCR and immune diagnostics will detect
live or dead cells. Also, all serovars of Chlamydia appear to be able to grow in cell
culture if the inoculum is centrifuged onto preformed, pretreated cell monolayers [98].
Culture based diagnostic methods are highly dependent upon the person performing the
cell culture, however, and inexperience can lead to poor results. The relatively long
period of time required (48-72 hours) and the necessity for highly skilled personnel to
gather the sample, perform the subsequent preparation, culturing, and microscopy of
Chlamydia make this method unsuitable for POC diagnostics [96-99]. Also, as
Chlamydia are obligate intracellular pathogens, they must be grown in a host cell, adding
an additional cost and complication to the procedure.

1.3.3 Direct Cytological Microscopy
While there are numerous molecular tools available for diagnostics, microscopy
still remains an invaluable method for diagnosing a number of diseases in the developing
and developed world. It is still considered one of the most common and reliable methods
for diagnosing two of the most prevalent disease in the developing world: tuberculosis
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and malaria [99-103]. Trachoma is also diagnosable by direct cytological examination via
the observation of typical intracytoplasmic inclusions. This type of screening is most
effective in detecting acute inclusion conjunctivitis in newborns, and it compares
favorably to culture based methods with a sensitivity of ~90% [100]. However, this form
of screening is relatively insensitive in regards to diagnosing conjunctivitis in adults. One
of the greatest difficulties in using microscopy in the diagnosis of trachoma is the
expense and limited availability of microscopes. Several recent developments have made
the use of microscopy more appealing for POC diagnostic purposes, however, including
light emitting diodes (LEDs) and the use of smart phones in place of a fluorescent
microscope. LEDs have many advantages over traditional mercury vapour fluorescent
bulbs: they are able to run on batteries, can be manufactured to produce a specific wave
length of light, negating the need for a filter, and they perform equally well without a
dark room [100–102]. In light of this, the WHO has recommended a shift away from
traditional fluorescent microscopy bulbs to LEDs [103]. The ability of a smart phone to
replace and function as a fluorescent microscope is a recent innovation. The Ozcan Group
at UCLA has created programs and minor attachments for smart phones which allow
them to read fluorescent signals and function as a microscope at a fraction of the cost of
traditional microscopy equipment [104]. While these advances have made microscopes
more readily available, difficulties in the wide-spread use of this method still remain, as
taking a proper image is only a portion of the problem. Trained personnel capable of
properly preparing, staining, and then analyzing and imaging the samples are still
required, representing the most significant barrier to the use of microscopy as a POC
diagnostic test.
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1.3.4 Electrochemical Detection
Electrochemical detection methods are used in several POC diagnostic devices,
most widely in the blood glucose assay. The modern glucose test meter functions based
on reading electrochemical signals generated by either glucose oxidase or glucose
dehydrogenase [105-107]. A blood sample is placed on a test strip and is then driven up
the strip due to capillary action. Glucose in the blood reacts with an enzyme on the
electrode containing glucose oxidase (or dehydrogenase). The enzyme is then reoxidized
with an excess of a mediator reagent, which is in turn reoxidised by the reaction
occurring at the electrode, generating a current which is then measured in order to
calculate the amount of glucose present [108]. While this works highly efficiently with
detecting the glucose levels in blood, many of the desired analytes lack glucose or
electoactive molecules. To overcome this, several studies have used Abs tagged with
either an electroactive molecule or an enzyme that converts an electrochemically silent
species into an active one, allowing for a singnal to be generated [109, 110]. Several
publications have shown that this technique has a very low LOD, with limits below 1 pM.
One study showed that Staphylococcal enterotoxin B could be captured with specific
antibodies (Abs) that were attached near the electrode, followed by the attachment of a
secondary Ab which was tagged with horseradish peroxidase in the presence of a set
amount of reactant, allowing them to measure and quantify very minute amounts of the
Staphylococcal enterotoxin B. [111-113].
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1.3.5 Enzyme-linked Immunosorbent assay
The enzyme-linked immunosorbent assay (ELISA) is the product of a series of
developments pioneered in the 1970’s which allowed for a highly sensitive test that is
relatively easy to perform when compared to culture-based methods. The ELISA
functions by using specific Abs against a desired antigen which are absorbed onto a
surface, typically a 96 well plate. This is a version of an ELISA known as a sandwich
ELISA, in which the antigen is then placed in the well with an additional primary Ab
which targets a separate antigen from the Abs bound to the well. Following a washing
and blocking procedure to inhibit and remove non-specific binding, a secondary Ab is
used which is conjugated to an enzyme (i.e. peroxidase) which will catalyze a color
change, denoting the presence or absence of the antigen [114].

There are currently several commercially available ELISAs for the detection of
Chlamydia which are relatively sensitive, with accuracies ranging from 62% to 98% and
specificities ranging from 92% to 100% depending on the sampling location and the
gender that the sample was derived from [115, 116]. While the specificity is high, it can
be jeopardized by cross-reactivity with other organisms. This cross-reactivity makes it
necessary, at times, to confirm a positive result by testing a sample via
immunofluorescence with a major outer membrane protein (MOMP)-specific monoclonal
Ab, or by blocking suspected antigens causing the false positive, a process which is
commonly included in some ELISA kits. Detecting false negative results presents an
additional problem, as the implausibility of checking all negative results leads to
insensitivity in the assay. While these problems do not prohibit ELISAs from being
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employed as a diagnostic method, they do make the test rather unsuited for POC
diagnostics in resource limited settings, as the test needs both a clean environment in
order to prevent contamination and trained personal to properly employ the test.

1.4 The “Optimal” POC Assay
There has been a substantial upsurge in both the development and the availability
of POC diagnostic tests for several diseases and medical conditions. The general push in
diagnostics has been for the creation of tests that are rapid and intuitive, most notably in
resource limited areas. While several different health and drug evaluation organizations
have created desired criteria for what could be described as the “optimal” POC diagnostic
assay, there are no rigid standards in the field. In 1988, a law entitled Recommendations
for Clinical Laboratory Improvement Amendments was passed by Congress, which
strictly regulates and monitors laboratory work that is considered complex and has a high
potential for error. It also includes a set of criteria by which a test may be waived from
these requirements if it met the U.S. Food and Drug Administration’s (FDA) definition of
a simple device. The FDA defines a simple device as: fully automated, unitized or selfcontained tests, using direct unprocessed samples, requiring only simple non-technique
dependent manipulation of sample or reagents, needing no operator analysis or
intervention, and having a simple to read and understand output requiring no calculations.
While these criteria were designed for simplicity in clinic diagnostic settings, they also
meet the desired parameters for a diagnostic test to be used in resource limited settings
[117]. The WHO has also created criteria for a POC test: a POC diagnostic test should be
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affordable by the population at risk, sensitive (>43%), specific (98%), easy to use and
interrupt, equipment-free, and accessible to the population which requires it [111]. These
two standards are an excellent place to start when looking to define the requirements for
an effective POC test for resource limited settings, in that it be simple to use and interrupt
by the lay person using it, with a high degree of specificity, is inexpensive relative to the
end user, and the sample used is easy to acquire and needs little to no processing.

1.5 Currently Available POC Diagnostics
1.5.1 Lateral Flow Assay
The LFA is a common tool for at-home and POC diagnostics, with commercially
available LFAs quickly becoming more prominent. LFAs function through the use of Abantigen interactions which target a specific antigen, followed by the use of a colorimetric
indicator, usually either gold colloidals or latex nanoparticles (np), to represent a positive
result [13]. The LOD and the sensitivity of these tests are limited, however, with 19%96% accuracy when compared to current detection methods such as PCR or culture
techniques. These tests are further limited by the use of the human eye and subjective
judgment to determine whether the test line has sufficient intensity to be considered
positive [13, 53, 54, 118-121].

LFAs have been used for decades in at-home pregnancy tests, and more recently
at-home tests for Acquired Immunodeficiency Syndrome (AIDS) and Chlamydia have
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become commercially available [121]. The principle of a LFA is based on two commonly
used molecular tools: immuno-labeling and -precipitation. In a commercially available
LFA, the sample is placed on a sample pad which, while porous, is used to exclude larger
particles that could block the capillaries in the porous membrane of the test strip. The
sample pad transports the sample into the conjugate pad. The conjugate pad contains an
amount of dried colloidal gold/latex-Ab conjugate, which is resolubilized when the
sample reaches it. Abs conjugated to the gold/latex form a complex with the target
antigen, if present in the sample. Capillary action drives the solution through the
conjugate pad and to the test strip, which contains the test and control line. When the
solution reaches the test line, which is comprised of a primary Ab for the target antigen,
the colloidial gold/latex–Ab-antigen complexes will be immobilized and concentrated,
representing a positive result (Figure 2a). Alternatively, if the antigen is absent or not
present in sufficient amounts, the colloidal gold-Ab conjugates will not be immobilized
in sufficient quantities to form a band, indicating a negative result (Figure 2b). The
validity of the test is affirmed by a control line placed past the test line which contains
either anti-IgG or a high concentration of the targeted antigen [121]. Previous results
have shown that the LOD of viruses with traditional colorimetric indicators is in the
range of 1x106 to 1x107 pfu/ml, while bacteria have a LOD between 200 to 5000 cells per
test, and depends on several factors: the antibodies chosen and whether they are
competitive, the purity of the sample used, and the rate at which the fluid moves through
the test strip [122,123].
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Figure 2. Schematic representation of a lateral flow assay (LFA) using the sandwich
mechanism. (a) Represents a positive result, and (b) a negative result. The sample to be
tested is premixed with an excess of reporter-antibody conjugate. If the desired antigen is
present in the sample, the conjugates will bind to it, creating a reporter-antibody-antigen
complex. Following the mixing of the sample, a LFA is dipped sample pad (colored
green)-first into the experimental or unknown sample to be tested. Capillary action drives
the sample solution through the sample pad and onto the nitrocellulose (shown in grey).
As the experimental or unknown sample moves past the ‘test line’, an area of
immobilized antibodies specific for the target antigen adsorbed to the nitrocellulose, the
reporter-antibody-antigen complexes in the sample are captured by the antibody. If
enough complexes are present, the reporter will become sufficiently concentrated in the
‘test line’ area to cause a visible color change on the test strip. Excess reporter-antibody
conjugates in the remaining solution will continue to move up the nitrocellulose by
capillary action (i.e. lateral flow), eventually encountering a ‘control line’ composed of
immobilized target antigen or anti-IgG. This ‘control line’ is designed to capture all
remaining conjugates in the sample, allowing the test to be validated through a forced
concentration of the reporter. Capillary action continues to drive the excess sample up the
nitrocellulose, where it is absorbed by the absorbent pad (yellow square).
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1.5.2 At-home Chlamydia Test Kit
There are now several commercially available POC tests for C. trachomatis, due
to rising demand for more rapid diagnostics to prevent and treat the spread of chlamydial
infections. However, it should be noted that these tests are designed primarily to diagnose
the sexually transmitted disease (STD), and the sampling materials provided in the kits
reflect this. The QuickVue® Chlamydia Test is a typical LFA, using colloidal gold and
latex np for its reporter, leading to a colorimetric indication. In a clinical study conducted
by the manufactures of the QuickVue® test, 723 women who were already attending a
STD clinic were tested. Of the 723 endocervical samples taken, 73 were positive for C.
trachomatis by culture and 67 were positive by the QuickVue® test, leading to an
accuracy of 81%, although there were 6 false positives. An additional study looking at
500 patients showed that the test had a sensitivity of 82.5% and specificity of 99%.
However, it should be noted that while the tests were performed by a random group of
people of varied education and background, the samples themselves were taken by
trained medical personnel at OBGYN and STD clinics, which likely skewed the numbers
in favor of greater sensitivity [124]. Furthermore, while the study checked potential false
positives in the case of the LFA showing a positive result while a culture method returned
negative via PCR, culture negative samples with a negative QuickVue® result were not
retested in this manner [124, 125].

Several publications evaluating the QuickVue® test and several other
commercially available tests lend credence to this assertion [126-129]. A study published
in 2002 used PCR as the standard for confirming or refuting the results of the

23

QuickVue® test. The study involved two groups of 100 women each: one group was
considered a high-risk population while the other was considered low-risk [128]. In the
high-risk population, the QuickVue® test had a sensitivity of 65% and a specificity of
100%. The sensitivity in the low-risk population was substantially lower at only 25%.
When both populations are taken into account, the sensitivity and specificity of the
QuickVue® test according to this study is 55% and 100% respectively, which is well
below the sensitivity reported by the manufactures on their website. These results are
further supported by a study published in 2010, in which three POC test kits which are
commercially available in the Netherlands, QuickVue®, Biorapid CHLAMYDIA Ag
test, and Handlab- C, were compared to PCR using a population of 763 people. All three
of these tests fell well below their advertised sensitivity, with QuickVue® reporting a
sensitivity of 25% and specificity of 99.7%. The Biorapid test had a sensitivity of 17%
and specificity of 93.7%. The Handlab- C test has a sensitivity of 22.5% and specify of
88.9%. While all three of the tests had a high degree of specificity the overall sensitivity
was poor, especially when compared to the advertised sensitivity of all three assays
which between the three claim sensitivity between 82% and 98% [130].
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CHAPTER 2
MATERIALS AND METHODS

2.1 Chemicals and Materials
Tetraethyl orthosilicate, tris(2,2’-bipyridyl)dichlororuthenium(II) hexahydrate
(Ru(bpy)32+), and L-lysine were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Streptavidin was obtained from Southern Biotech (Birmingham, AL, USA). 3glycidoxypropyl trimethoxysilane (GOPTMS) was purchased from AcrosOrganics (NJ,
USA). Absolute ethanol, acetone, methanol, toluene, hydrochloric acid, sodium chloride,
sodium hydroxide, Triton X-100, Tween-20, Tris, and BSA were purchased from Fisher
Scientific (Fair Lawn, NJ, USA). Sodium phosphate dibasic, Potassium phosphate
monobasic, NS borax (sodium tetraborate) were obtained from Sigma-Aldrich Chemical
Company (Milwaukee, WI, USA). All chemicals used in this study were analytical
reagent grade. Nitrocellulose membrane, and absorbent pad were purchased from GE
Healthcare Bio-Sciences Corp. (Piscataway, NJ, USA). Chlamydia antibodies were
purchased from Fitzgerald Industrial International (Acton, MA, USA). T7-tag
biotinylated monoclonal antibodies and T7 antibodies were purchased from Novagen®,
an affiliate of Merck (San Diego, CA, USA). Anti-IgG antibodies were purchased from
ABcam (Cambridge, MA, USA). All solutions and buffers were prepared using ultrapure
water from Barnstead Nanopure InfinityTM ultrapure water system (Thermo Scientific,
Dubuque, IA, USA). E . coli BL21 stock was purchased from EMD Millipore(Billerica,
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Massachusetts ) and wild-type bacteriophage T7 stock was purchased directly from
ATCC (BAA-1025-B2, Manassas, Virginia).

2.2 Apparatus
A multi-mode microplate reader (SynergyTM 2) was obtained from BioTek
Instruments, Inc. (Winooski, VT, USA). A dispenser (Linomat IV) was purchased from
American Laboratory Trading Inc. (East Lyme, CT, USA).

2.3 T7 Bacteriophage Working Stock Preparation
E . coli BL21 culture was grown overnight in 50 ml of Luria Broth (LB), pH 7.5,
at 37 °C with shaking. 1 ml of overnight culture was then added to 200 ml of fresh LB
and incubated at 37 °C with shaking until an optical density (OD) of at least .6 at 600 nm
was reached (an OD of .627 was reached after 3.5 hours). Then 20 µl of T7 stock was
added to the E . coli BL21 culture and allowed to incubate, with shaking, at 37 °C for 1.5
hours. 5 g of NaCl was added to the 200 ml culture. The culture was then split into six 35
ml tubes and spun at 8,000 RPM on a Fiberlite F21-8x50y fixed angle rotor
(Thermoscientific, Waltham, MA) for 10 minutes at room temperature. Supernatant was
collected and filtered through .22 µm SCFA filter (Corning Life Science, Corning, NY).
40 ml of this filtered culture was divided into four 13.5 ml ultracentrifuge tubes and spun
at 35,000 RPM for 2 hours on a Fiberlite F65L-6X13.5 fixed angle rotor
(Thermoscientific) at room temperature. Supernatant was removed and pellets in each
tube were resuspended in 1 ml of 25 mM MES buffer, pH 6.0, and then combined for a
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total of 4 ml of purified T7 working stock. The titer (4.4 X 1011 pfu/ml) of this purified
T7 working stock was determined following the double agar overlay plaque assay as
outline.

2.4 Preparation and Assembly of Lateral Flow Assay
Plastic transparency with dimensions of 75mm x 215 mm was used as the
backing for the LFA. “Sticky” tape from 3M with a width of 38 mm was purchased and
used as the adhesive to bind the nitrocellulose to the plastic backing. The “sticky” tape
was applied to the plastic transparency between the 10mm and 48mm position vertically
on the plastic.

Nitrocellulose type AE 98 was purchased from Whatman. A 38 mm x 215 mm x 5
µm piece of nitrocellulose was used in the production of each set of LFAs. The
nitrocellulose was handled with gloves to prevent contamination, and was placed flush
with the adhesive in order to prevent air bubbles from forming.

Following the addition of plastic backing to the nitrocellulose, the test and
control lines were added. The lines were placed on the nitrocellulose uniformly through
the use of a Linomat IV. The amount of Ab applied to each line was 1.9 µg/cm. The test
line was applied at 29 mm and the control line was placed at 38 mm to allow for proper
alignment for fluorescent readings. Following application of each line, the Linomate was
sterilized with 10% bleach followed by three washes with DI water to prevent
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contamination between the test and control line Abs. After both the test and control line
were applied, the backed nitrocellulose was allowed to dry in a vacuum oven at 28° C
and 16.8 pka for 2 hours.

Following drying, the nitrocellulose was blocked in a buffer of 1% BSA, 10 mM
Tris, and 100 mM NaCl for 1 hour at pH 7.4. The assay was then removed and excess
liquid was blotted away with a chemwipe. The sample was then washed 5 times in 0.1%

Tween-20, 10 mM Tris, and 100 mM NaCl for 5 min to remove excess BSA.
After the washing process the LFA was then dried overnight at 28° C and 16.8 pka

28

Plastic backing
Adhesive

Place
Adhesive

Place
Nitrocellulo
se

Nitrocellulose
Control line
Test line
Blocking Solution
Blocked nitrocellulose
29

Sample Pad

Spray Test
and Control
Line

Overnight
Drying

Absorbent
Pad
Block

Overnight
Drying ,
Cut, and
add
Adhesive

Blot then
Wash

Add Sample
and
Absorbent
Pad

30

Figure 3. Manufacture of a Lateral Flow Assay (LFA) test strip. Plastic backing (solid, white) is cut into a 75 x 215 mm sheet. A
38 x 215 mm piece (gray, spotted) of adhesive is then placed between 10 mm and 48 mm. A 38 x 215 mm piece of nitrocellulose
(colored light grey) is then firmly applied to the adhesive. The test line (blue, line), which is composed of IgG that targets the primary
antigen, is then aspirated by the Linomate IV onto the nitrocellulose. The control line (red, line), which is comprised of anti-IgG or the
target antigen, is then aspirated onto the nitrocellulose. The sheet with the applied test and control lines is then dried overnight at low
humidity. The sheet is then placed in a blocking solution [(light blue), 1% BSA, 10 mM Tris, and 100 mM NaCl at pH 7.4] for 1 hour.
Following the blocking, the sheet is blotted dry and placed in a wash solution (0.1% Tween-20, 10 mM Tris, and 100 mM NaCl at pH
7.4) for 5 min, after which it is blotted dry again. The previous step is repeated 4 additional times. Following the washing, the sample
is then dried overnight in low humidity. The sheet is then cut into 4 mm strips, and adhesive is applied above and below the
nitrocellulose. An absorbent pad (colored yellow) and sample pad (colored green) are then adhered to the test strip.

a

b

c

d

e

Figure 4. Determination of blocking time. The nitrocellulose represented here is the
same as was used in our LFAs and was blocked for variable amounts of time as follows:
(a) 20 sec, (b) 1 min, (c) 10 min, (d) 30 min, and (e) 1 hr. The base (bracketed area) of the
test strips labeled ‘a’ through ‘d’ display nonspecific binding (as revealed by the red
coloration), while test strip labeled ‘e’ displays no nonspecific binding at the base (no red
color). Determined that blocking must be conducted for at least 1 hour.

2.5 Conjugation of Gold Nanoparticles with Streptavidine to Biotinylated T7tagged Abs
250 µl of gold np bound to streptavidin was added to 1375 µl of HPLC water. The
OD was then checked at 520 nm to confirm it equaled one. 2.83 µg of biotinylated Ab
was then added to the gold np solution. The solution was then placed on a shaker, at low
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speed, and incubated at room temperature for 45 min. Following shaking, 170 µl of 10%
BSA at pH 9 was added to halt the reaction. This was followed by incubation at room
temperature for 20 min shaking gently. Following the 20 min incubation, the sample was
centrifuged at 5000 g at 4° C for 20 min. The supernatant was then removed and the
precipitate was re-suspended in 2 mM Borax at pH 9. The OD at 520 nm was then taken.

2.6 Conjugation of Naked Gold Nanoparticles to Chlamydial Abs
A kit was purchased from BioAssay Works which provided naked gold np and the
necessary buffers to perform the reaction. 0.5 ml of naked gold np at OD 15 was placed
into a clean micro centrifuge tube. 6 µl of Buffer A, provided, and 4 µl of Buffer B,
provided, were added to bring the reaction mixture to pH 7.3. Following, 4.2 µl of antichlamydia polyclonal Abs at 5 mg/ml, suspended in 1x PBS, were added to the reaction
mixture. The sample was incubated at room temperature for 30 minutes, shaking gently.
The reaction was halted by the addition of 50 µl of BSA Blocking Stabilizer Solution,
provided.

2.7 Test Conditions for Gold Nanoparticles in a LFA for T7 Bacteriophage
Serial dilations were performed from 1x 1011 to 1x 103 pfu/ ml at 1 log intervals,
with the negative control consisting of 1x PBS. Each sample was tested three independent
times. 30 µl of a sample was placed in a 1.5 ml microcentrifuge tube and to it was added
20 µl of a dynamic blocking buffer (0.2% BSA, 0.3% Tween-20, 0.1% polyethylene
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glycol, 0.2% NaN3, 100 mM Tris pH 8) and 15 µl of gold np-Ab conjugate. It was
incubated at room temperature on a shaker at medium speed for 10 min and then the
mixed sample was placed into a larger reservoir. The LFA was placed into the reservoir
and the sample was allowed to run up the test. After 30 min the LFA was transferred to a
new sample well which was loaded with 80 µl of washing buffer (0.1% Tween-20,
100mM NaCl, 10mM Tris pH 7.4) to remove any nonspecific binding. The LFA was
removed 2 hours later, and an image taken of the results immediately, as excessive time
between completion of the assay and reading can lead to false positives.

2.8 Running Conditions for Gold Nanoparticles in Chlamydia LFAs
Serial dilutions were performed (1x PBS with 10mM EDTA pH 7.4) from 1x 104
to 3.33x 101 pfu/ ml at 1/10 log intervals with the negative control sample consisting of
1x PBS. Each sample was tested three independent times. 30 µl of a sample was placed in
a 1.5 ml microcentrifuge tube and to it was added 20 µl of a dynamic blocking buffer
(0.2% BSA, 0.3% Tween-20, 0.1% polyethylene glycol, 0.2% NaN3, 100 mM Tris pH 8)
and 5 µl of gold np-Ab conjugate. It was incubated at room temperature on a shaker at
medium speed for 10 min and then the mixed sample was placed into a larger reservoir.
The LFA was placed into the reservoir and the sample was allowed to run up the test.
After 30 min the LFA was transferred to a new sample well which was loaded with 80 µl
of washing buffer (0.1% Tween-20, 100mM NaCl, 10 mM Tris pH 7.4) to remove any
nonspecific binding. The LFA was removed 2 hours later, and an image taken of the
results immediately, as excessive time between completion of the assay and reading can
lead to false positives.
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2.9 Preparation of Ru(bpy)32+-doped Silica Nanoparticles
RuSNP were prepared in aqueous medium by using a basic amino acid catalysis
method [132]. Briefly, Ru(bpy)32+ and tetraethyl orthosilicate (TEOS) were added to a
reaction system by using three steps in order to control the size of the nanoparticles and
the amount of the dye Ru(bpy)32+ incorporated inside each nanoparticle. First, 36.1 mg of
L-lysine was added as a basic catalyst to 36 ml of deionized water in a
polytetrafluoroethylene (PTFE) bottle reactor. After the L-lysine was completely
dissolved, 0.04 M Ru(bpy)32+ solution with the designated volume was added under the
agitation to the reactor. Next, TEOS used as a silica source with designated volume was
added and mixed in the reactor. Finally, the reactor was put into a 90 °C silicone bath
while stirring at 500 rpm. The Ru(bpy)32+ solution and the TEOS were added to the
system three times in intervals of 24 hours. In a representative case, the volumes of the
Ru(bpy)32+ solution/TEOS added were 50 μl/2.7 ml, 400 μl/5.4 ml, and 400 μl/5.4 ml,
respectively. After the hydrolysis of TEOS was completed, orange-colored RuSNP
solution was dialyzed in deionized water for 48 hours in order to remove the nonincorporated dye and L-lysine in the solution. The deionized water was changed three
times during the dialysis. The particles were then concentrated by centrifugation (30,000
x g at 4°C, 60 minutes). Finally, the RuSNP were washed twice in absolute ethanol and
dried in a vacuum oven (16.8 kPa, 40 °C).
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2.10 Surface modification of Ru(bpy)32+-doped Silica Nanoparticles
A portion (2.3 mg) of dried RuSNP were re-suspended in 4.5 mL dry toluene in a
20 mL glass vial and sonicated at room temperature for one hour. Then, 0.5 mL of
GOPTMS was added to the vial which was placed into a 65 °C water bath while shaking
at 200 rpm for 2 hours. The pellet was collected following centrifugation (10,000 x g at 4
°

C, 30 minutes), and then sequentially washed in dry toluene, acetone, and ethanol, and

dried in a vacuum oven overnight (16.8 kPa, 25 °C). The GOPTMS-modified RuSNP
(RuSNP-GOPTMS) were immediately used or stored at 4 °C for later usage.

2.11 Conjugation of Fluorescent Nanoparticles to Abs
280 µl of PBS (40 mM NaCl, 50 mM sodium phosphate buffer, pH 9) was added
to 0.4 mg of RuSNP-GOPTMs in a 1.5 ml centrifuge tube and sonicated for 5 min.
Following, 150 µg of Ab was addedto the solution which was inverted at room
temperature for one hour. Following the one hour incubation at room temperature, the
solution was placed on a shaker at medium speed at 4° C for 48 hours. 280 µl of blocking
buffer(100 mM Tris, 40 mM NaCl, 1% BSA pH 7.4) was added to halt the reaction, and
allowed to incubate overnight at 4° C, shaking.
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Figure 5. Schematic diagram of the surface modificiation of Ru(bpy)32+-doped silica
nanoparticles (RuSNP). RuSNPs first undergoe silinization, followed sequentially by
the surface addition of GOPTMS and the addition of Abs to be conjugated to them.
TEOS: tetraethyl orthosilicate, RuSNP: Ru(bpy)32+-doped silica nanoparticles, GOPTMS:
3-glycidoxypropyl trimethoxysilane. This graphic was made using ‘Chem Draw’ and
previous set pieces made by Juhong Chen of the Nugen Lab Group.

2.12 Running Conditions for Fluorescent Nanoparticles with T7
Bacteriophage
Serial dilutions were performed from 1x 1011 too 1x 103 pfu/ ml at 1 log intervals
with the negative control consisting of 25 mM MES. Each sample was tested three
independent times. 30 µl of a sample was placed in a 1.5 ml microcentrifuge tube and to
it was added 20 µl of a dynamic blocking buffer (0.2% BSA, 0.3% Tween-20, 0.1%
polyethylene glycol, 0.2% NaN3, 100 mM Tris pH 8) and 15 µl of fluorescent np- Ab
conjugate. It was incubated at room temperature on a shaker at medium speed for 10 min
and then the mixed sample was placed into a larger reservoir. The LFA was placed into
the reservoir and the sample was allowed to run up the test. After 30 min the LFA was
transferred to a new sample well which was loaded with 60 µl of washing buffer (0.1%
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Tween-20, 100 mM NaCl, 10 mM Tris pH 7.4) to remove any nonspecific binding. The
LFA was removed 1 hour later, and loaded into the fluorescent plate reader and the
results were recorded.

Figure 6. Running a lateral flow assay (LFA) test strip. (a) The sample is added to the
reaction mixture (reporter-Ab conjugate and flow buffer) and (b) incubated for 10 min at
27 °C with agitation. (c) Following the incubation, the LFA is placed sample pad-first
into the sample mixture. (d) The sample mixture is then driven by capillary action up the
LFA. Following a 30 min incubation, a wash buffer (0.1% Tween-20, 100 mM NaCl, 10
mM Tris pH 7.4) is added in order to (e) remove unbound reporter-Ab conjugate.
Following the 1 hr incubation, the LFA is (f) removed from the test tube. Images are
taken of LFAs that use colorimetric reporters, while fluorescent-based LFAs are loaded
into the (g) cassette. It is then placed into a fluorometer and the fluorescent signal is (h)
read and recorded

2.13 Fluorescent Running of Chlamydia
Serial dilutions were preformed (1x PBS with 10 mM EDTA pH 7.4) from 1x 104
to 3.33x 101 pfu/ ml at 1/10 log intervals with the negative control sample consisting of
1x PBS and 10 mM EDTA. Each sample was tested three independent times. 30 µl of a
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sample was placed in a 1.5 ml microcentrifuge tube and to it was added 20 µl of a
dynamic blocking buffer (0.2% BSA, 0.3% Tween-20, 0.1% polyethylene glycol, 0.2%
NaN3, 100 mM Tris pH 8) and 5 µl of fluorescent np- Ab conjugate. It was incubated at
room temperature on a shaker at medium speed for 10 min and then the mixed sample
was placed into a larger reservoir. The LFA was placed into the reservoir and the sample
was allowed to run up the test. After 30 min the LFA was transferred to a new sample
well which was loaded with 80 µl of washing buffer (0.1% Tween-20, 100 mM NaCl, 10
mM Tris pH 7.4) to remove any nonspecific binding. The LFA was removed 2 hours
later, and loaded into the fluorescent plate reader and the results were recorded.
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CHAPTER 3
RESULTS
3.1 The LOD of Traditional Colorimetric Reporters Used in LFAs is
Insufficient to Detect Medically Relevant Viral Loads
T7 bacteriophage was chosen as the antigen for the proof-of-concept testing for
several reasons. First, it is a well understood virus with a wide variety of both polyclonal
and monoclonal Abs available. It is also easy to maintain, handle, and propagate a large
stock of T7 bacteriophage, due in part to its short life cycle (17 min at 37˚C), which
allows for rapid growth of the viral population. Furthermore, its host cell, E. coli, is also
very easy to maintain and propagate. T7 also has the added benefit of not being a human
pathogen, which allows for safer and easier handling.

Previous reports have shown that current colorimetric reporters are incapable of
detecting viruses at medically relevant levels. However, LFA sensitivity varies depending
upon the Abs used and the exact manufacturing process. A baseline was therefore needed
in order to validate the LOD of the LFAs used in this study, and to confirm that any
improvement in LOD is due to the use fluorescent reporters and not due to a difference in
design.

A traditional LFA was performed with colloidal gold np acting as the reporter. A
30 µl sample was used, leading to an observed LOD of 1x106 pfu/ml (Figure 7), which is
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within range of previously reported LOD for LFAs designed to detect viruses [1-7,
13].While these results are similar to previously reported findings, they are of insufficient
sensitivity to detect acute and subclinical infections, or even serious infection in many
cases [100-103]. People infected with HIV, for instance, typically do not have a viral load
above 10,000 copies/ml in the early stages of the disease. In fact, the amount of HIV
needed to determine if the patient is likely to develop AIDS is a viral load >100,000
copies/ml within six months of seroconversion [100,102]. The current LOD for LFAs
using colloidal gold is 2 logs below the LOD required to properly diagnose HIV.
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Figure 7. A lateral flow assay (LFA) using a colorimetric reporter to detect T7
bacteriophage. The ‘+ Control’ is the area of the test strip (i.e. LFA) that will indicate
whether a valid (red line present) or invalid (no line present) test occurred. The ‘Test line’
is an area of immobilized antibodies specific for the target antigen adsorbed to the
nitrocellulose. The reporter-antibody-antigen complexes in the sample are captured by
the antibody, and if enough complexes are present, the reporter will become sufficiently
concentrated in the ‘test line’ area to cause a visible color change on the test strip (red
line present). However, if no antigen is present, the reporter-antibody conjugates will not
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be captured, indicating a negative result (no line present) of a given sample run through
the test strip. The negative control without any T7 is shown in panel (a). The remaining
solutions contain T7 at concentrations of (b) 9x105, (c) 1x106, (d) 1x107, (e) 1x108, or (f)
1x109 PFU/mL. This experiment was repeated 3 times, with a representative shown here.
In this experiment a concentration of 1 x 106 PFU/mL was needed to display a positive
result, which was also seen in the other 2 experiments.

3.2 Fluorescent Reporters are Capable of Detecting Viral Loads at Medically
Relevant Levels
Since it has been demonstrated that current colorimetric reporters are insufficient
for detecting viral loads at medically relevant levels, a change in reporter is needed in
order for LFAs to become a valid option. Fluorescent- based reporters offer the potential
to greatly improve the LOD of LFAs due to several factors. First, a fluorescent- based
assay is read by a fluorometer, which provides a quantitative numerical value. By
comparison, colorimetric reporters are qualitative, requiring end-user subjective judgment
to determine a positive or negative result. Furthermore, the fluorometer has substantially
greater acuity then the human eye and is capable of detecting fluorescent concentrations
as low as one part per trillion. These factors should allow for a fluorescent-based reporter
to greatly improve the LOD of a LFA.

Two distinct fluorophores were used in our assays: fluorescein isothiocyanate
(FITC) and Ru(bpy)32+-doped silica np (RuSNP). FITC was chosen as a baseline
fluorescent molecule for several reasons: it is a commonly used in immuno-fluorescent
staining, fluorescence-activated cell sorting, and is a well understood fluorophore.
RuSNP was chosen due to its distinctive optical properties [131, 132]. Several of the
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properties that make it an optimal fluorophore are its large Stokes Shift (an excitation of
460 nm and an emission of 620 nm), and its comparatively long excitation state (650 ns
in aqueous solutions). It is therefore likely that RuSNP- based reporters will allow for
LFAs to detect viral concentrations at medically relevant concentrations

The fluorescent signal of FITC (dotted line, Figure 8) and fluorescent np (solid
line, Figure 8) increased in a concentration-dependent manner and reached a signal to
background ratio (S/B) of 1.65 and 2, respectively, at the viral concentration of 1x106
PFU/mL. The LOD was determined for the FITC labeled experiments to be 5x104
PFU/mL. This value was based on the S/B being three standard deviations above the
background noise, with the S/B of FITC at 5x104 PFU/mL being 1.18. The fluorescent np
LOD was determined to be 5x103 PFU/mL, with a S/B of 1.26. Statistical analysis was
performed on the reported values, and the p-value for FITC at 5x104 PFU/mL was 0.003
with a standard deviation of ~2%, representing a high degree of both significance and
reproducibility. For the fluorescent np at 5x103 PFU/mL, the p-value was <0.0001 with a
standard deviation of ~4%, also representing a high degree of significance and
reproducibility.

These results show that fluorescent based reporters, particularly RuSNP, are
capable of detecting viral levels at medically relevant concentrations, as the LOD of
RuSNP was determined to be 5,000 PFU/mL, which is below the average viral
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Figure 8. Fluorescent reporters improve the limit of detection (LOD) of a lateral
flow assay (LFA). The ratios of signal to background (S/B) in the presence of different
concentrations of T7 bacteriophage are shown. The S/B is determined by dividing the
signal from a test with varying concentrations of T7 bacteriophage by the signal of a
negative control without T7 (background). Data shown are the mean of five independent
measurements presented with their standard deviation. The fluorescent signal of FITC is
represented by a dotted line and the signal from fluorescent np is represented by a solid
line. (*) The LOD for RuSNP was determined to be 5x103 PFU/mL because the S/B was
more than three standard deviations above 1 (background). The signal was 1.26 with a
standard deviation of ~4%. The signal values were compared to the background values
via the one tailed unpaired t-test, with a p-value <0.0001. (**) The LOD for FITC was
determined to be 5x104 PFU/mL. This was determined by the S/B being greater than
three standard deviations above 1 (background). The signal was 1.18 with a standard
deviation of ~2%. The signal values were compared to the background values via the one
tailed unpaired t-test, with a p-value of 0.003. RuSNP is a substantial improvement over
colorimetric based reporters in current LFAs.

concentration found in HIV patients. RuSNP is a substantial improvement over
colorimetric based reporters in current LFAs.
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3.3 The LOD of Traditional Colorimetric Reporters Used in LFAs is
Insufficient to Reliably Detect C. trachomatis EBs
It has been previously shown that colorimetric reporters do not have a sufficiently
low LOD for the detection of viral loads at concentrations typically found in patients.
Furthermore, previous reports have shown that current colorimetric reporters used in
LFAs are incapable of reliably detecting Chlamydial EBs at medically relevant levels.
Several studies have shown that the sensitivity of the LFAs currently available for the
detection of C. trachomatis have a sensitivity between 17-25% and have a LOD between
200 to 5000 cells per test [122, 123]. However, a single C. trachomatis EB is capable of
causing an infection, so the optimal assay would be able to reliably detect a single EB.
The variations inherent in using a different set of Abs and assembly processes required
that a baseline be performed in order to validate the LOD of the LFAs used in this study,
and to confirm that any improvement in LOD is due to the use of fluorescent reporters
and not a difference in design and test running process.

3.3.1 Fouling in a LFA Designed to Detect C. trachomatis Elementary Bodies
In this experiment fouling was observed, indicating that the particle size of the
sample is larger than expected, as chlamydial elementary bodies are 300nm and are small
enough to flow through the pores in the nitrocellulose.
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Figure 9. Fouling in a lateral flow assay (LFA) using a colorimetric reporter to
detect C. trachomatis elementary bodies. The ‘+ Control’ is the area of the test strip
(i.e. LFA) that will indicate whether a valid (red line present) or invalid (no line present)
test occurred. The ‘Test line’ is an area of immobilized antibodies specific for the target
antigen adsorbed to the nitrocellulose. The reporter-antibody-antigen complexes in the
sample are captured by the antibody, and if enough complexes are present, the reporter
will become sufficiently concentrated in the ‘test line’ area to cause a visible color
change on the test strip (red line present). However, if no antigen is present, the reporterantibody conjugates will not be captured, indicating a negative result (no line present) of
a given sample run through the test strip. The arrow is indicating fouling, which occurs
due to the particle size of the sample being larger than the pore size found in the
nitrocellulose. The negative control without any C. trachomatis elementary bodies is
shown in panel (a). The remaining solution contains C. trachomatis elementary bodies at
a concentration of (b) 1x104 IFU/mL. This experiment was repeated 2 times, with a
representative shown here.

Fouling was observed at the base of the LFA (Figure 9b, arrow). As the
negative control (Figure 9a) did not exhibit any signs of fouling and the positive controls
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on the tests were observed as valid (red line visible), the issue is unlikely to be due to a
lack of blocking. Several potential problems could be responsible for the fouling issue.
The first possibility is that the reporter-Ab conjugate could be acting as a cross-linker
between multiple EBs, leading to a larger particle size. These cross-linked particles
would then be large enough to block the pores in the nitrocellulose membrane, preventing
additional material from flowing up the strip. The second possibility is that the EBs are
aggregating due to excess Ca2+ and Mg2+ ions, which are present in large amounts due to
the nature of the sample used, which is a cell lysate mixture chosen to mimic a sample
taken from a patient.

3.3.2 The Fouling is not Due to Cross-Linking of the Reporter-Ab Conjugate to
Multiple EBs
In order to test if the reporter-Ab conjugates are acting as a cross-linker, an
additional series of LFA were run with several changes in methodology. The C.
trachomatis sample was not incubated with the reporter-Ab conjugate. Instead, the
sample was run directly up the test strip using a wash buffer to push excess sample
through the test strip. After the sample had fully run up the strip, the reporter-Ab
conjugate was added and run up the sample, and subsequently followed by a wash buffer
to remove any nonspecific binding of the reporter-Ab conjugate. The changes in
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Figure 10. Cross-linking is not the cause of fouling in a lateral flow assay (LFA)
using a colorimetric reporter to detect C. trachomatis elementary bodies. The ‘+
Control’ is the area of the test strip (i.e. LFA) that will indicate whether a valid (red line
present) or invalid (no line present) test occurred. The ‘Test line’ is an area of
immobilized antibodies specific for the target antigen adsorbed to the nitrocellulose. The
reporter-antibody-antigen complexes in the sample are captured by the antibody, and if
enough complexes are present, the reporter will become sufficiently concentrated in the
‘test line’ area to cause a visible color change on the test strip (red line present).
However, if no antigen is present, the reporter-antibody conjugates will not be captured,
indicating a negative result (no line present) of a given sample run through the test strip.
The arrow is indicating fouling, which occurs due to the particle size of the sample being
larger the pore size found in the nitrocellulose. The negative control without any C.
trachomatis elementary bodies is shown in panel (a). The remaining solution contains C.
trachomatis elementary bodies at a concentration of (b) 1x104 IFU/mL. This experiment
was repeated 2 times and a representative is shown here. Fouling was still observed
despite running the reporter antibody conjugate up the test strip (i.e. LFA) following the
C. trachomatis sample, ruling out cross linking as a possible cause of the fouling.
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methodology allow for the Abs to interact with their antigens for the same amount of
time, but prevent cross-linking from occurring in the early portions of the test stip.

Fouling was still observed at the base of the LFA (Figure 10b, arrow). As seen
previously, the negative control (Figure 10a) did not exhibit any signs of fouling and the
positive controls on the tests were observed as valid (red line visible). Therefore, the
cross-linking of multiple reporter-Ab conjugates and EBs is not the underlying cause for
the fouling that is occurring in the nitrocellulose membrane.

3.3.3 The Fouling is Due to Excess Ca2+ and Mg2+ Ions Leading to EB Aggregation
In order to determine if the EBs were aggregating due to excess Ca2+ and Mg2+
ions in the raw lysate sample, a zeta-potential and particle size analyzer was used to
measure the size of the particles in two differing samples. One sample was cell lysate
diluted in PBS to a concentration of 1x104 IFU/mL, while the second sample was
prepared with a PBS buffer with the addition of 5 mM of EDTA, as EDTA acts as a
chelating agent and will scavenge the Ca2+ and Mg2+ ions. With the excess positively
charged ions inter-chelated, the negatively charged outer membrane of the Chlamydial
EBs would prevent aggregation and disperse currently aggregated EBs.
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Table 1. The particle size of C. trachomatis samples. The size of particles in a sample
and their relative amount at a concentration of 1x104 IFU/mL in PBS. Data of three
independent measurements are presented, with an error margin of one standard deviation.
The chlamydial elementary bodies are aggregating, since the size of the elementary
bodies is 896.4 ± 15.4 nm, which is almost three times larger than the reported size of a
single elementary body.

Table 2. The particle size of C. trachomatis sample with EDTA. The size of particles
in a sample and their relative amount at a concentration of 1x104 IFU/mL treated with 5
mM EDTA. Data of three independent measurements are presented, with an error margin
of one standard deviation. The addition of EDTA significantly alleviates the aggregation
of elementary bodies, as their average size is 300.9 ±2.5 nm following treatment, which is
the reported size of a single elementary body.

The samples that were not treated with EDTA (Table 1) contain three major
particle sizes. The peak, which constitutes the largest volume of the particles accounting
for 64.5% of the total particles suspended in the sample, is at 896 nm. As one EB has a
diameter of 300 nm, this peak likely suggests that the EBs are aggregating. This
conjecture is confirmed as the sample treated with EDTA (Table 2) displayed three
distinct particle sizes. The peak, which constitutes the largest volume of the particles,
accounting for 89.6% of the total particles suspended in the sample, is at 300 nm which is
the size of a single EB.
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These results demonstrate that the presence of excess Ca2+ and Mg2+ ions due to
cell lysate cause the Chlamydial EBs to aggregate. These larger particle sizes are the
likely underlying cause of the fouling of the LFA.

3.3.4 The LOD of Traditional Colorimetric Reporters Used in LFAs is Insufficient
to Reliably Detect C. trachomatis EBs
As the aggregation issue was resolved, the testing of the LFA designed to detect
C. trachomatis, with the colorimetric reporter, could proceed. A 30 µl sample of raw cell
lysate was used, leading to an observed LOD of 9x103 cfu/ml (Figure 11d), which is
within range of previously reported LOD for LFAs designed for Chlamydial EBs [1-7,
14].While these results are similar to previously reported findings, and are adequate for
detecting the levels of C. trachomatis found in infected tissues and secretions, several
studies have shown that LFAs offer poor sensitivity even using samples taken by trained
professionals [120-122]. It is therefore likely that the reported LOD of this test would be
substantially higher when used in a real-world setting, and could very well be several
orders of magnitude off. A change in the reporter used from colorimetric to fluorescent
would allow for an increase in sensitivity and lower the LOD of the LFA.

50

a

b

c

d

e

+ Control
Test line

Figure 11. A lateral flow assay (LFA) using a colorimetric reporter to detect C.
trachomatis serovar E. The ‘+ Control’ is the area of the test strip (i.e. LFA) that will
indicate whether a valid (red line present) or invalid (no line present) test occurred. The
‘Test line’ is an area of immobilized antibodies specific for the target antigen adsorbed to
the nitrocellulose. The reporter-antibody-antigen complexes in the sample are captured
by the antibody, and if enough complexes are present, the reporter will become
sufficiently concentrated in the ‘test line’ area to cause a visible color change on the test
strip (red line present). However, if no antigen is present, the reporter-antibody
conjugates will not be captured, indicating a negative result (no line present) of a given
sample run through the test strip. The negative control without any C. trachomatis
elementary bodies is shown in panel (a). The remaining solutions contain C. trachomatis
elementary bodies at concentrations of (b) 7x103, (c) 8x103, (d) 9x103, or (e) 1x104
IFU/mL. This experiment was repeated 3 times and a representative is shown here. In this
experiment a concentration of 9 x 103 PFU/mL was needed to display a positive result,
which was also seen in the other 2 experiments.
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3.4 Fluorescent Reporters are Capable of Detecting Very Low Levels of
Chlamydial EBs
Since it has been demonstrated that current colorimetric reporters lack the
sensitivity to reliably detect Chlamydial EBs at levels typically found in infected tissues,
a change in reporter is needed in order for LFAs to become a reliable option. Fluorescent
based reporters offer the potential to greatly improve the LOD of LFAs. As the benefits
of fluorescent reporters has been previously demonstrated in the detection of viral
particles, a similar study was initiated for improving the LOD of LFAs for the detection
of Chlamydial EBs.

3.4.1 Aggregation of Ru(bpy)32+-doped Silica Nanoparticles
Fouling was observed at the base of both LFAs (Figure 9a & b, arrow). As both
the negative control and the positive test had fouling occur, the underlying cause of
fouling in the sample is likely due to the RuSNP-Ab conjugate. There are several
potential underlying causes which could be responsible for the fouling issue. The first
possibility is that the RuSNP-Ab conjugate could be aggregating due to insufficient
charge on the surface due to the variation of the number of primary amines accessible to
epoxy attack on the polyclonal Abs. The second possibility is that there are insufficient
Abs compared to RuSNPs, leading to the attachment of multiple RuSNPs to a single Ab,
although this is unlikely as the amount of Ab needed to fully coat 0.4 mg of
nanoparticles, 50nm in diameter, is 100 μg and an excess of 150 μg was used.
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Figure 12. Aggregation of Ru(bpy)32+-doped Silica Nanoparticles (RuSNP). A LFA
using a RuSNP reporter used to detect C. trachomatis. ‘+ Control’ is an indicator of a
valid (white line present) or invalid (no line present) test. The ‘Test line’ is an area of
immobilized antibodies specific for the target antigen adsorbed to the nitrocellulose. The
reporter-antibody-antigen complexes in the sample are captured by the antibody, and if
enough complexes are present, the reporter will become sufficiently concentrated in the
‘test line’ area to cause a visible color change on the test strip (red line present).
However, if no antigen is present, the reporter-antibody conjugates will not be captured,
indicating a negative result (no line present) of a given sample run through the test strip.
The arrow is indicating fouling. The negative control without any C. trachomatis is
shown in panel (a). The remaining solution contains C. trachomatis at the concentration
of (b) 1x104 IFU/mL. This experiment was repeated two times, with a representative
shown here. In this experiment fouling is occurring at the base of the strip and is due to
RuSNP aggregation rather than chlamydial elementary body aggregation.
Zeta potentials were taken and the charge was 19 mV, which is below the 25 mV
charge required on a particle in order to maintain stability in solution. The exact cause of
this lower zeta potential is currently unknown.
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3.4.2 FITC improves the limit of detection (LOD) of a lateral flow assay (LFA)
As there were difficulties in the employment of the RuSNP-Ab conjugate as a
reporter, and the underlying point was to improve the LOD of the LFA, a different
fluorescent reporter was used. Since FITC was previously used in the T7 bacteriophage
study, FITC was chosen as a replacement for RuSNP until a solution for the aggregation
could be devised.

The fluorescent signal of FITC (dotted line Figure 13) increased in a
concentration-dependent manner and reached a S/B of 1.25, at the EB concentration of
1x104 IFU/mL. The LOD was determined to be 1x103 IFU/mL for the FITC labeled
experiments. This value was based on the S/B being three standard deviations above the
background noise, with the S/B of FITC at 1x103 IFU/mL being 1.19. Statistical analysis
was performed on the reported values and the p-value for FITC at 1x103 IFU/mL was
0.0004 with a standard deviation of ~3%, representing a high degree of both significance
and reproducibility. The data provided here demonstrates the potential for fluorescent
reporters to detect very low levels of EBs, with the LOD being ~30 EBs per test.
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Figure 13. FITC improves the limit of detection (LOD) of a lateral flow assay (LFA).
The ratios of signal to background (S/B) in the presence of different concentrations of C.
trachomatis elementary bodies are shown. The S/B is determined by dividing the signal
from a test with varying concentrations of C. trachomatis elementary bodies by the signal
of a negative control without C. trachomatis elementary bodies (background). Data are
the mean of three independent measurements and are presented with their standard
deviation. (*) The LOD for RuSNP was determined to be 1x103 IFU/mL. This was
determined by the S/B being greater than three standard deviations above 1 (background).
The signal was 1.19 with a standard deviation of ~3%. The signal values were compared
to the background values via the one tailed unpaired t-test, with a p-value 0.0004. FITC is
a substantial improvement over colorimetric based reporters in LFAs.
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CHAPTER 4
DISCUSSION
The data presented here, combined with previously published studies,
demonstrate the current poor performance of traditional LFAs with relation to the
diagnosis of potential viral pathogens and C. trachomatis infections. It should be noted
that the traditional LFAs performed in this study were done under substantially better
conditions and with samples that were more uniform than what would occur under POC
diagnostic conditions. It also should be noted that the LFAs used in this study will likely
lose some sensitivity as they are further developed, since the assays lacked both sample
and conjugated pads which do decrease the amount of sample that reaches the test strip.
This study provides compelling evidence that the use of fluorescent molecules,
especially RuSNP, can greatly increase the sensitivity of the LFA. As previously
discussed, the sensitivity of the RuSNP is 2.5 logs more sensitive than the colorimetric
reporter, greatly improving the LFA and allowing for the potential use of LFAs to
diagnosis viral pathogens. FITC labeled Abs also improved the sensitivity of LFAs with
regards to the detection of C. trachomatis and, should the complications of conjugating
the polyclonal Abs to the RuSNP be overcome, there will likely be a similar
improvement in the sensitivity of the assay.

Complications occurred with the conjugation process of the polyclonal Abs to the
RuSNP. It is likely due to the polyclonal nature of the Abs used, which in turn allowed
for there to be a differing number of primary amines exposed for conjugation. This
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variation likely allowed for the different Abs to bind to multiple RuSNP. The variable
nature of the number of RuSNP bound to each polyclonal AB is likely is the cause for the
differing charges seen, leading to a zeta potential of 19 mV which is well below the 25
mV needed in order to maintain a stable suspension. In order to make the RuSNP
function with polyclonal Abs, a blocking reagent with a primary amine that is heavily
charged is needed in order to prevent static interaction from occurring, preventing
aggregation. The other potential solution is the use of monoclonal Abs for conjugation to
the RuSNP, as this will likely prevent substantial variations in the charge of the protein
covered RuSNP from occurring, alleviating the low zeta potential and preventing the
aggregation from occurring.

While there is more refinement required to fully exploit fluorescent reporters for
use in LFAs, the data shown gives substantial credence to the potential of fluorophores as
reporters in LFAs, which could greatly increase the sensitivity and accuracy of the test in
POC settings.
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APPENDIX
CHLAMYDIA TRACHOMATIS DEVELOPMENTAL CYCLE
C. trachomatis has a biphasic developmental cycle consisting of an infectious EB
and a replicative, metabolically active reticulate body (RB). The EBs are spore-like
infectious bodies that are metabolically inert, but stable in extracellular environments.
The chlamydial nucleoid is located off-center in the cell body of the EB, and is highly
compacted due to histone-like proteins HctA and HctB condensing nuclear material [133,
133]. Unlike other gram-negative bacteria, Chlamydia strains appear to lack a
peptidoglycan (PG) layer [135], yet the EBs are able to maintain structural integrity under
a diverse set of conditions. It has been postulated that inter- and intramolecular cysteine
bonds exist between cysteine-rich proteins (CRPs) OmcB, OmcA, and OmpA, and that
these CRPs, in conjunction with the major outer membrane protein (MOMP) and other
membrane components, form a supramolecular structure that provides rigidity to the EB
and allows it to resist turgor pressure. Additionally, there is a hexagonally arrayed protein
layer, composed primarily of OmcB, at the inner surface of the outer-membrane complex
that is thought play a role in the cellular stability of EBs [136-139].
Attachment and Entry
Infectious EBs attach to the host cell initially by electrostatic interactions [140].
The electrostatic interactions are thought to form predominantly due to sulfated
macromolecules on the surface of the host cells. The knockout of genes encoding for host
cell sulfation, the transport of sulfanted proteins to the surface, such as
glucuronosyltransferase I, galactosyltransferase I, 3′-phosphoadenosine 5′-
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phosphosulfate, and other related genes has an inhibitory effect on the attachment of C.
trachomatis to host cells [140-142]. Following the initial electrostatic interaction, an
irreversible secondary attachment occurs.

Following attachment, C. trachomatis mediates host cytoskeleton rearrangement,
which leads to a transient reorganization of the microvilli and the formation of pedestallike structures beneath the attached EB [144, 145]. This rearrangement is induced, in part,
by an effector protein, translocated actin recruiting phosphoprotein (Tarp), that is injected
into the host cell via a type III secretion system (TS3) [146]. Tarp is a likely candidate for
the mediation of host cytoskeletal rearrangement due to its distinct actin binding and
oligomerization domains. These domains allow the clustering of multiple actin monomers
to nucleate and form new actin filaments [147]. Actin filament polymerization has been
shown to be an important part of chlamydial entry into host cells, as treatment of host
cells with an actin polymerization inhibitor, such as cytochalasin D, inhibits the uptake of
C. trachomatis [148]. Additionally, when host cells are microinjected with Abs specific
to the actin binding domain found on Tarp prior to C. trachomatis infection, entry is
inhibited [149].

The rearrangement of the host cytoskeleton, while likely induced by Tarp, is
further mediated by Rac GTPase recruitment of WAVE2 and Abi-1 followed by the
activation of the host actin related protein 2 and 3 (Arp 2/3) nucleating complex
[150,151]. The disruption of the Arp2/3 complex leads to the inhibition of chlamydial
entry [152]. While Tarp is capable of Arp 2/3-independent recruitment of actin, the level
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of actin rearrangement required for chlamydial entry into host cells likely means that
Tarp and the Arp 2/3 complex operate cooperatively to increase the rate of actin filament
formation. The precise mechanism of actin rearrangement is not fully understood [153].
Primary Differentiation
Within the inclusion, the EB undergoes primary differentiation, shifting from an
infectious EB to a metabolically active RB. The process of differentiation can be blocked
by treatment with antibiotics that specifically inhibit transcription or translation,
suggesting that de novo protein production is required for intracellular growth [154].
Primary differentiation begins with chromosomal decondensation, causing the genome to
become transcriptionally active. At this point, the EB contains large quantities of mRNA
and ribosomes, even though they were previously metabolically inert. This ‘carryover’
mRNA primarily encodes for late gene products predominantly used during secondary
differentiation, when RBs become EBs. These late gene products, such as HtcA, if
translated, would have a deleterious effect on the newly differentiating Chlamydia cells.
Chlamydia cells appear to have a mechanism to differentiate newly transcribed mRNA
from ‘carryover’ mRNA, allowing only for the translation of newly transcribed mRNA. It
is currently unclear how Chlamydia species (spp.) discriminate between carryover
mRNA and newly transcribed mRNA. It should be noted that the carryover mRNA is
rapidly degraded in the bacterial cell and generally drops below detectable levels within 6
h post-infection (PI) [155].
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Transcription begins within the differentiating RB almost immediately following
internalization, with new protein expression detectable within 15 min PI [156, 157].
Genes expressed during primary differentiation serve two general purposes: establishing
systems involved in nutrient acquisition (e.g. ADP/ATP translocase, nucleotide
phosphate transporter, oligopeptide permease, D-alanine/glycine permease, malate
dehydrogenase, nucleoside phosphohydrolase, and a methionine aminopeptidase), and
modifying the inclusion to prevent its entry into the endocytic pathway leading to
lysosomal fusion (e.g. inclusion-associated protein (Inc) -like genes CT228 and CT229,
and the EEA1-like CT147) [155, 158, 159].
Inclusion Modification
Following entry into the host cell, the EB remains within the inclusion and does
not fuse with the lysosome or endosome. The inclusion membrane separates EBs from
the host cytosol and prevents passive diffusion of molecules greater than 520 Da [160].
While the inclusion does not fuse with the lysosomes or endosomes, it maintains the
ability to selectively intercept a wide range of host vesicles [161-163]. This is due, in
part, to proteins that all Chlamydia spp. secrete that localize to the inclusion membrane,
collectively termed Incs, and the lack of late endosomal and lysosomal markers on the
inclusions [164-166].

Rab GTPases regulate host vesicle fusion, and studies have identified several Rab
proteins, including Rab1, Rab6, Rab10, Rab11, and Rab14, which are re-localized to
chlamydial inclusions PI and are essential for bacterial survival and reproduction [167-
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169]. In C. trachomatis, the Inc protein CT229 interacts with Rab4 and in C. pneumoniae
the Inc Cpn0585 interacts with Rabs1, 10, and 11 [170, 171]. When these interactions are
disturbed, in the case of C. trachomatis, with microinjection of anti-CT229 into infected
cells, chlamydial development is inhibited [172]. Similarly, in the case of C. pneumoniae
Cpn0585 was ectopically expressed in infected cells and interfered with chlamydial
development [49]. The mechanisms mediating Rab6 recruitment are currently unknown,
but the silencing of Rab6 decreased the formation of EBs at later points in chlamydial
development. In addition to Rab proteins, soluble N-ethylmaleimide sensitive factor
attachment protein receptor (SNARE) and Syntaxin 6 have been found to co-localize with
the chlamydial inclusion. It should also be noted that SNARE-like motifs have been
detected in Chlamydia Incs and possibly represent a mimicry mechanism which allows
Chlamydia to specifically manipulate vSNAREs to the inclusion target membrane, which
in turn allow it to manipulate membrane fusion [173, 174]. It has also been noted that the
inhibition of Golgi fragmentation has an inhibitory effect on the growth of Chlamydia
spp., while increased fragmentation of the Golgi promotes growth [169].
Cell Division
The RB arises from the internalized EB following primary differentiation. RBs
are 1 μm in size. The cytoplasm appears granular with a diffuse nucleoid. RBs are noninfectious and have an inner and outer membrane, resembling other Gram-negative
eubacteria. Following the conversion to RBs, they begin to undergo binary fission
throughout this portion of the developmental cycle.
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Unlike other eubacteria, Chlamydia spp. lack an identifiable ftsZ ortholog, which
encodes a protein centrally involved in bacterial cell division and found in all other
sequenced eubacteria. Interestingly, chlamydial spp. contain a complete set of genes for
the synthesis of PG (murABCDEF), even though several studies have reported that
Chlamydia EBs lack PG [175- 178]. This apparent lack of PG is made even more peculiar
as Chlamydia spp. contain penicillin binding proteins (Pbp) and are sensitive to penicillin
and other β-lactam antibiotics [177, 178]. It has been hypothesized that the RBs
synthesize small amounts of PG, which plays a role in bacterial cell division by perhaps
substituting for the lack of FtsZ in the formation of nascent division septa.
MurA gene expression was detected early in the chlamydial cell cycle and murB
was expressed approximately 6 h later [179]. Additionally, microarray analysis
demonstrated that murABCDEF transcripts were not present before 16 h PI, with the
highest levels being expressed 40 h PI [175]. This coincides with the time frame that
Chlamydia undergoes binary fission. Further evidence supporting this idea has shown
that Chlamydia has genes encoding for both Pbp2 and MreB. This is unusual, since MreB
is found predominantly in rod-shaped bacteria. There is now evidence that Chlamydia
uses MreB in place of FtsZ as the central coordinator of cell division machinery, and this
guides the PG to the division septa [180].
Secondary Differentiation
After approximately 36 h, the RBs begin to differentiate into EBs; the signal for
this process is currently unknown. Despite the accumulation of 500 to 1000 infectious
EBs in the inclusion, host cell function is minimally disrupted [181]. Expression of a
number of late-cycle genes occurs during secondary differentiation, including genes that
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encode components of the outer membrane complex (e.g. OmcA, OmcB, and OmpA)
and proteins involved in the condensation of the chromosome (e.g. HctA and B)
[175,182].

At ~48 h, the release of EBs occurs through one of two mechanisms: host cell
lysis, thought to be mediated by calcium dependent permeabilization of the host cell
membrane, or through the extrusion of the whole inclusion, which is dependent upon host
cell actin polymerization [182, 183]. The underlying mechanisms which determine which
exit strategy is employed are not currently understood. It has been hypothesized that the
ability of Chlamydia infections to shed away EBs while leaving behind viable infected
cells is part of a cellular persistence mechanism.
Persistence
Several Chlamydia-induced diseases are associated with chronic infection and
inflammation (e.g. PID and reactive arthritis). Chlamydia spp. are capable of entering a
persistent state with altered growth characteristics, with enlarged pleomorphic RBs that
do not differentiate into EBs or undergo binary fission, but continue to replicate their
chromosomes. The conditions that induce a state of persistence in Chlamydia are well
known, including penicillin treatment, amino acid starvation, IFN-γ, monocyte infection,
and phage infection, and the removal of the underlying factors reverses the persistent
state, allowing binary fission and secondary differentiation to resume [181-183]. While
the conditions to induce persistence are well understood, the exact molecular mechanism
by which Chlamydia spp. enter persistence is currently unknown. Several studies have
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shown that a number of early genes were up-regulated, particularly the euo gene, which
encodes a DNA-binding protein that binds to the late gene promoter region omcAB [182].
Also, several genes involved with RB to EB differentiation are down-regulated (i.e.
hctAB, omcAB, MOMP, and ompA) during a state of persistence [183]. The persistent
state seems to allow for Chlamydia spp. to survive the host immune response and other
stresses, priming for rapid division following the alleviation of the stress.
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